Clinical pharmacology review of safinamide for the treatment of Parkinson's disease

被引：45
作者：
Fabbri, Margherita [1 ]
Rosa, Mario M. [1 ,2 ,3 ]
Abreu, Daisy [1 ,2 ]
Ferreira, Joaquim J. [1 ,2 ,3 ]
机构：
[1] Inst Med Mol, Clin Pharmacol Unit, Lisbon, Portugal
[2] Hosp Santa Maria, Ctr Hosp Lisboa Norte, Dept Neurosci, Serv Neurol, Lisbon, Portugal
[3] Univ Lisbon, Fac Med, Lab Clin Pharmacol Therapeut, Lisbon, Portugal
来源：
NEURODEGENERATIVE DISEASE MANAGEMENT | 2015年 / 5卷 / 06期
关键词：
advanced Parkinson's disease; MAO-B inhibitor; Parkinson's disease; safinamide;
D O I：
10.2217/nmt.15.46
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
Safinamide (Xadago (TM)) is an oral alpha-aminoamide derivative marketed for the treatment of Parkinson's disease (PD). The drug has both dopaminergic properties, namely highly selective and reversible inhibition of monoamine oxidase B, and nondopamimetic properties, namely selective sodium channel blockade and calcium channel modulation, with consequent inhibition of excessive glutamate release. In 2014, safinamide was approved in the European Economic Area, as "an add-on therapy to stable dose levodopa, alone or in combination with other PD therapies in mid-to late-stage-fluctuating PD patients." In addition, evidence has been provided for safinamide in the treatment of motor symptoms in early PD patients. This article summarizes the pharmacological properties, development program, clinical indications for PD treatment, stratified according to several disease's stages and the safety profile of safinamide. A meta-analysis of the most frequent adverse events among Phase III trials has been also performed.
引用
收藏
页码：481 / 496
页数：16
相关论文
共 39 条
  • [1] Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature
    Ahlskog, JE
    Muenter, MD
    [J]. MOVEMENT DISORDERS, 2001, 16 (03) : 448 - 458
  • [2] [Anonymous], 1997, 9750238 PHARM UPJ
  • [3] [Anonymous], 1997, 9750104 PHARM UPJ
  • [4] Barone P, 2013, NEUROLOGY, V1
  • [5] Barone P, 2015, 19 INT C PARK DIS MO
  • [6] Structures of human monoamine oxidase B complexes with selective noncovalent inhibitors: Safinamide and coumarin analogs
    Binda, Claudia
    Wang, Jin
    Pisani, Leonardo
    Caccia, Carla
    Carotti, Angelo
    Salvati, Patricia
    Edmondson, Dale E.
    Mattevi, Andrea
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2007, 50 (23) : 5848 - 5852
  • [7] Two-Year, Randomized, Controlled Study of Safinamide as Add-on to Levodopa in Mid to Late Parkinson's Disease
    Borgohain, Rupam
    Szasz, Jozsef
    Stanzione, Paolo
    Meshram, Chandrashekhar
    Bhatt, Mohit H.
    Chirilineau, Dana
    Stocchi, Fabrizio
    Lucini, Valentina
    Giuliani, Rodolfo
    Forrest, Emma
    Rice, Patricia
    Anand, Ravi
    [J]. MOVEMENT DISORDERS, 2014, 29 (10) : 1273 - 1280
  • [8] Randomized trial of safinamide add-on to levodopa in Parkinson's disease with motor fluctuations
    Borgohain, Rupam
    Szasz, J.
    Stanzione, P.
    Meshram, C.
    Bhatt, M.
    Chirilineau, D.
    Stocchi, F.
    Lucini, V.
    Giuliani, R.
    Forrest, E.
    Rice, P.
    Anand, R.
    [J]. MOVEMENT DISORDERS, 2014, 29 (02) : 229 - 237
  • [9] Safinamide - From molecular targets to a new anti-Parkinson drug
    Caccia, C.
    Maj, R.
    Calabresi, M.
    Maestroni, S.
    Faravelli, L.
    Curatolo, L.
    Salvati, P.
    Fariello, R. G.
    [J]. NEUROLOGY, 2006, 67 (07) : S18 - S23
  • [10] Caccia C, 2001, 0901003 NEWR PHARM
1234